DD Stock Analysis: Dupont De Nemours | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 18.854m USD | 12M Return: 51.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 177M
EPS Trend: 39.5%
Qual. Beats: 1
Rev. Trend: -59.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DuPont de Nemours, Inc. (NYSE: DD) is a global technology-based materials and solutions provider operating across the United States, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa. The company is organized into two reporting segments: Healthcare & Water Technologies and Diversified Industrials, serving end markets that include medical devices, water treatment, construction, automotive, aerospace, printing, and packaging.
The company markets a wide portfolio of well-known specialty brands. Healthcare and water-related offerings include TYVEK-based protective and packaging materials, AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and INGE and ITEGRATEC ultrafiltration modules. Construction-oriented products include TYVEK house wrap, STYROFOAM insulation, and CORIAN solid surface. Industrial offerings include Vespel parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL structural adhesives, and Cyrel flexographic printing plates.
DuPont de Nemours is classified in the GICS Materials sector under the Diversified Chemicals sub-industry, reflecting its broad exposure to specialty chemicals and engineered materials rather than a single end market. The current entity was incorporated in 2015 and adopted the DuPont de Nemours name in June 2019 following the unwinding of the DowDuPont merger, with shares listed on the NYSE under the ticker DD.
- Electronics materials revenue tracks semiconductor cycle recovery
- Construction weakness pressures Tyvek and insulation volumes
- Water technologies grows on industrial and desalination demand
| Net Income: -29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.06 > 1.0 |
| NWC/Revenue: 36.48% < 20% (prev 15.03%; Δ 21.46% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.29b > Net Income -29.0m |
| Net Debt (2.43b) to EBITDA (1.74b): 1.39 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.6m) vs 12m ago -1.36% < -2% |
| Gross Margin: 33.79% > 18% (prev 32.76%; Δ 1.03% > 0.5%) |
| Asset Turnover: 33.79% > 50% (prev 33.88%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: 3.39 > 6 (EBIT TTM 962.0m / Interest Expense TTM 284.0m) |
| A: 0.17 (Total Current Assets 5.64b - Total Current Liabilities 2.10b) / Total Assets 21.4b |
| B: -1.13 (Retained Earnings -24.2b / Total Assets 21.4b) |
| C: 0.03 (EBIT TTM 962.0m / Avg Total Assets 28.7b) |
| D: 1.95 (Book Value of Equity 14.0b / Total Liabilities 7.21b) |
| Altman-Z'' = -0.33 = B |
| DSRI: 0.93 (Receivables 1.70b/2.29b, Revenue 9.70b/12.2b) |
| GMI: 0.97 (GM 32.76% / 33.79%) |
| AQI: 0.87 (AQ_t 0.58 / AQ_t-1 0.66) |
| SGI: 0.80 (Revenue 9.70b / 12.2b) |
| TATA: -0.06 (NI -29.0m - CFO 1.29b) / TA 21.4b) |
| Beneish M = -3.34 (Cap -4..+1) = AA |
As of July 29, 2026, the stock is trading at USD 139.96 with a total of 1,079,292 shares traded. Over the past week, the price has changed by +3.10%, over one month by +3.11%, over three months by +0.32% and over the past year by +51.36%.
Current recommended Stop Loss: 134.60 (which is 3.8% or 1.2 ATR below the current price).
Dupont De Nemours has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy DD.
- StrongBuy: 11
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 169.6 | 21.2% |
P/E Trailing = 121.4261
P/E Forward = 19.4553
P/S = 2.7254
P/B = 1.3347
P/EG = 1.7173
Revenue TTM = 9.70b USD
EBIT TTM = 962.0m USD
EBITDA TTM = 1.74b USD
Long Term Debt = 3.13b USD (from longTermDebt, last quarter)
Short Term Debt = 40.0m USD (from shortTermDebt, last quarter)
Debt = 3.18b USD (from shortLongTermDebtTotal, last quarter) + Leases 9.00m
Net Debt = 2.43b USD (calculated: Debt 3.18b - CCE 752.0m)
Enterprise Value = 21.3b USD (18.9b + Debt 3.18b - CCE 752.0m)
Interest Coverage Ratio = 3.39 (Ebit TTM 962.0m / Interest Expense TTM 284.0m)
EV/FCF = 19.23x (Enterprise Value 21.3b / FCF TTM 1.11b)
FCF Yield = 5.20% (FCF TTM 1.11b / Enterprise Value 21.3b)
FCF Margin = 11.41% (FCF TTM 1.11b / Revenue TTM 9.70b)
Net Margin = -0.30% (Net Income TTM -29.0m / Revenue TTM 9.70b)
Gross Margin = 33.79% ((Revenue TTM 9.70b - Cost of Revenue TTM 6.42b) / Revenue TTM)
Gross Margin QoQ = 35.81% (prev 31.13%)
Tobins Q-Ratio = 0.99 (Enterprise Value 21.3b / Total Assets 21.4b)
Interest Expense / Debt = 8.93% (Interest Expense 284.0m / Debt 3.18b)
Taxrate = 21.39% (160.0m / 748.0m)
NOPAT = 756.2m (EBIT 962.0m * (1 - 21.39%))
Current Ratio = 2.68 (Total Current Assets 5.64b / Total Current Liabilities 2.10b)
Debt / Equity = 0.23 (Debt 3.18b / totalStockholderEquity, last quarter 14.0b)
Debt / EBITDA = 1.39 (Net Debt 2.43b / EBITDA 1.74b)
Debt / FCF = 2.19 (Net Debt 2.43b / FCF TTM 1.11b)
Total Stockholder Equity = 18.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.10% (Net Income -29.0m / Total Assets 21.4b)
RoE = -0.16% (Net Income TTM -29.0m / Total Stockholder Equity 18.5b)
RoCE = 4.45% (EBIT 962.0m / Capital Employed (Equity 18.5b + L.T.Debt 3.13b))
RoIC = 4.00% (NOPAT 756.2m / Invested Capital 18.9b)
WACC = 9.62% (E(18.9b)/V(22.0b) * Re(10.06%) + D(3.18b)/V(22.0b) * Rd(8.93%) * (1-Tc(0.21)))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -84.05 | Cagr: -1.83%
[DCF] Terminal Value 71.00% ; FCFF base≈1.11b ; Y1≈1.11b ; Y5≈1.16b
[DCF] Fair Price = 92.03 (EV 14.9b - Net Debt 2.43b = Equity 12.4b / Shares 135.0m; r=9.62% [WACC]; 5y FCF grow -0.72% → 2.50% )
EPS Correlation: 39.47 | EPS CAGR: 4.95% | SUE: 1.50 | # QB: 1
Revenue Correlation: -59.40 | Revenue CAGR: -4.54% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.68 | Chg30d=-4.88% | Revisions=-12% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.85 | Chg30d=-4.37% | Revisions=-38% | Analysts=14
EPS current Year (2026-12-31): EPS=6.88 | Chg30d=-3.93% | Revisions=-50% | GrowthEPS=+36.4% | GrowthRev=+4.5%
EPS next Year (2027-12-31): EPS=7.58 | Chg30d=-3.37% | Revisions=-18% | GrowthEPS=+10.2% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: -39% (up=7, down=18)